• Bayer Healthcare, of Whippany, N.J., said the FDA approved Adempas (riociguat) tablets to treat adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) after surgical treatment or inoperable CTEPH to improve exercise capacity and WHO functional class; and to treat adults with pulmonary arterial hypertension to improve exercise capacity, improve WHO functional class and delay clinical worsening.